News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Genetown
Matritech, Inc.'s NMP22(R) BladderChek(R) Test Could Save Lives And Reduce Expense In Screening High Risk Populations For Bladder Cancer
May 22, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Independent Study from University of Texas Southwestern Reports NMP22(R) BladderChek(R) Test could be Beneficial for Detecting Cancer Earlier in High Risk Populations.
Twitter
LinkedIn
Facebook
Email
Print
MORE ON THIS TOPIC
Job Trends
Massachusetts’ Life Sciences Job Growth Slows, but 10-Year Outlook Remains Strong: Report
June 12, 2024
·
4 min read
·
Angela Gabriel
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
·
4 min read
·
Lorenzo Soliman
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
·
3 min read
·
Greg Slabodkin
FDA
Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy
May 7, 2024
·
4 min read
·
Tyler Patchen
